A Safety Study of SGN-CD33A in AML Patients

NCT01902329 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

195

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myelogenous Leukemia
Acute Myeloid Leukemia
Acute Promyelocytic Leukemia

Interventions

DRUG: HMA
DRUG: SGN-CD33A

Sponsor

Seagen Inc.